Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05669950 · ClinicalTrials.gov registry record · Phase 1
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
A Phase 1 study of Congenital Adrenal Hyperplasia, sponsored by H. Lundbeck A/S.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 17
- Study locations
NCT05669950: Recruiting Phase 1 study of Congenital Adrenal Hyperplasia, sponsored by H. Lundbeck A/S.
NCT05669950 is a Phase 1 study of Congenital Adrenal Hyperplasia that is actively recruiting participants, run by H. Lundbeck A/S. The registered enrollment target is 42 participants, below the 97-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (57% lower). The trial reports 17 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05669950, a Phase 1 study of Congenital Adrenal Hyperplasia, is actively recruiting participants, sponsored by H. Lundbeck A/S.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 17
- Study locations
Study Summary
This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH is a rare genetic disorder that affects a person's ability to produce certain hormones. The main goals of this trial are to learn about the safety and tolerability of Lu AG13909, how Lu AG13909 behaves in the body, and how the body responds to Lu AG13909.
Conditions Studied
Interventions
- DRUG Lu AG13909
Study Locations (17)
Other
- Rigshospitalet - Copenhagen
- Chu Angers - Angers
- CHU de Lille - Lille
- GH Pitié-Salpêtrière - Paris
- CHRU Strasbourg - Strasbourg
- David Metreveli Medical Centre, Tbilisi - Tbilisi
- Beaumont Hospital Royal College of Surgeons in Ireland (RCSI), Dublin - Dublin
- Azienda Ospedaliero Universitaria di Bologna - Bologna
- Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma - Roma
- Centrum Nowoczesnych Terapii, Dobry Lekarz - Dobry Lekarz
- Sahlgrenska University Hospital - Gothenburg
- Karolinska University Hospital - Stockholm
- NIHR/Wellcome Trust Clinical Research Facility - Birmingham
- Cambridge Clinical Research Centre - Cambridge
- NIHR Clinical Research Facility - London
- University College London Hospital - NIHR - London
Michigan
- University Hospital-University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT05669950 shows while recruiting
NCT05669950 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 97-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Congenital Adrenal Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which Lu AG13909 is the first listed.
NCT05669950 lists 17 locations in 2 states (Other, Michigan).
Frequently Asked Questions
What is clinical trial NCT05669950 about?
NCT05669950 is a clinical study titled "A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia". This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH is a rare genetic disorder that affects a person's ability to produce certain hormones. The main goals of this trial are to learn about the safety and...
What is the current status of trial NCT05669950?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2022-12-19. Estimated completion is 2027-12-31.
What conditions does trial NCT05669950 study?
This clinical trial studies the following conditions: Congenital Adrenal Hyperplasia.
What interventions are being tested in trial NCT05669950?
The interventions under investigation include: Lu AG13909 (DRUG).
Who is sponsoring clinical trial NCT05669950?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05669950 being conducted?
This trial has 17 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Adrenal Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05669950's enrollment target sits among peer trials
42 6th of 8 higher than 3 of 8 other Congenital Adrenal Hyperplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Adrenal Hyperplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)
ACTIVE NOT RECRUITING · Phase 1
-
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
COMPLETED · Phase 1
-
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
RECRUITING · Phase 3
-
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
RECRUITING · Phase 2
-
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI